Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Manmeet Ahluwalia MD, FACP, MBA

Manmeet Ahluwalia MD, FACP, MBA

Deputy Director, Chief of Medical Oncology, and Chief Scientific Officer, Miami Cancer Institute, Miami, Florida

Dr. Manmeet Ahluwalia is the Chief Scientific Officer, Chief of Medical Oncology, and Deputy Director and Fernandez Family Endowed Chair in Cancer Research at Baptist Health Miami Cancer Institute. Previously, he was the Dean and Diane Miller Family Endowed Chair in Neuro-Oncology in the Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center (BBTC), Cleveland Clinic, Ohio, where he subspecialized in treatment of patients with brain tumors and brain metastases. He was also a Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

A neuro-oncologist, Dr. Ahluwalia's research focuses on the development of new therapies for patients with brain tumors and brain metastases. He is currently leading several clinical trials involving new targeted therapies as well as immunotherapeutic approaches. His research has been presented nationally and internationally and has resulted in over 175 editorials, peer-reviewed manuscripts, and book chapters.

Recent Contributions to PracticeUpdate:

  1. ASCO: Intracranial Activity of Selpercatinib for RET Fusion-Positive NSCLC
  2. Nivolumab + Ipilimumab With and Without Local Therapy in Patients With Melanoma Brain Metastases
  3. Emerging Data for Brain Metastases From HER2+ Breast Cancer
  4. Immunotherapy for Glioblastoma
  5. Osimertinib in Patients With EGFR Mutation–Positive NSCLC and Leptomeningeal Metastases
  6. Implications of Updated CATNON Data for Radiation and Temozolomide in Gliomas
  7. Circulating Myeloid-Derived Suppressor Cells as a Predictor for Patients Treated With Nivolumab and Bevacizumab for Recurrent GBM
  8. Update on Immunotherapy and Targeted Therapy for Brain Metastases
  9. Dendritic Cell Vaccine ICT-107 Triggers Immune Activation and Prolongs PFS in Glioblastoma
  10. Outcomes of Preexisting and Newly Discovered Brain Metastases During Treatment With Anti–PD-1 in Patients With Metastatic Melanoma

Most Read This Week

Recently Updated